drugset / Trial / NCT00032084
S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
Phase 3
Terminated
10 enrolled
SWOG Cancer Research Network
Cancer and Leukemia Group B · collabEastern Cooperative Oncology Group · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
RATIONALE: A program that includes bupropion may be more effective in helping early-stage lung cancer patients to quit smoking. It is not yet known if a program to quit smoking is more effective with or without bupropion. PURPOSE: Randomized phase III trial to determine the effectiveness of a program to quit smoking with or without bupropion in treating patients who have undergone surgery for stage I or stage II non-small cell lung cancer.
Timeline
- Start
- 2002-01
- Primary completion
- 2004-02
- Completion
- 2004-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bupropion | Small molecule | 300 mg | Oral |
| Comparator | Nicotine | Unknown | 21 mg | Other |